- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05806931
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer (SCOTI)
Sequential Combined TAS-102 and Oxaliplatin Alternating With TAS-102 and Irinotecan (Sequential TASOXIRI) With Bevacizumab for Late-Line Metastatic Colorectal Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Howard S. Hochster, MD
- Phone Number: 732-253-5618
- Email: howard.hochster@rutgers.edu
Study Locations
-
-
New Jersey
-
Elizabeth, New Jersey, United States, 07202
- Recruiting
- Trinitas Hospital and Comprehensive Cancer Center
-
Contact:
- Howard S. Hochster, MD
- Phone Number: 732-253-5618
- Email: howard.hochster@rutgers.edu
-
Jersey City, New Jersey, United States, 07302
- Recruiting
- RWJBarnabas Health Jersey City Medical Center
-
Contact:
- Howard S. Hochster, MD
- Phone Number: 732-253-5618
- Email: howard.hochster@rutgers.edu
-
Lakewood, New Jersey, United States, 08701
- Recruiting
- RWJBarnabas Health - Monmouth Medical Center Southern Campus
-
Contact:
- Howard S. Hochster, MD
- Phone Number: 732-253-5618
- Email: howard.hochster@rutgers.edu
-
Livingston, New Jersey, United States, 07039
- Recruiting
- Cooperman Barnabas Medical Center (Saint Barnabas Medical Center)
-
Contact:
- Howard S. Hochster, MD
- Phone Number: 732-253-5618
- Email: howard.hochster@rutgers.edu
-
Long Branch, New Jersey, United States, 07740
- Recruiting
- RWJBarnabas Health - Monmouth Medical Center
-
Contact:
- Howard S. Hochster, MD
- Phone Number: 732-253-5618
- Email: howard.hochster@rutgers.edu
-
New Brunswick, New Jersey, United States, 08903
- Recruiting
- Rutgers Cancer Institute of New Jersey
-
Contact:
- Howard S. Hochster, MD
- Phone Number: 732-253-5618
- Email: howard.hochster@rutgers.edu
-
New Brunswick, New Jersey, United States, 08903
- Recruiting
- RWJBarnabas Health - Robert Wood Johnson University Hospital
-
Contact:
- Howard S. Hochster, MD
- Phone Number: 732-253-5618
- Email: howard.hochster@rutgers.edu
-
Somerset, New Jersey, United States, 08873
- Recruiting
- RWJBarnabas Health - Robert Wood Johnson University Hospital
-
Contact:
- Howard S. Hochster
- Phone Number: 732-253-5618
- Email: howard.hochster@rutgers.edu
-
Toms River, New Jersey, United States, 08755
- Recruiting
- RWJBarnabas Health - Community Medical Center
-
Contact:
- Howard S. Hochster
- Phone Number: 732-253-5618
- Email: howard.hochster@rutgers.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed stage IV colon cancer (AJCC 7th edition) that has progressed after standard therapy that included 5-FU, irinotecan, oxaliplatin and appropriate antibody therapy. Antibody therapy with bevacizumab and an anti-EGFR antibody, if RAS wild type, should have been given unless medical reasons have precluded their use. Participants who could not tolerate standard agents because of unacceptable, but reversible toxicity necessitating their discontinuation will be allowed to participate.
- Participants who had received adjuvant chemotherapy and had recurrence during or within six months of completion of the adjuvant chemotherapy will be allowed to count the adjuvant therapy as one chemotherapy regimen for advanced disease.
- Progression of disease must be documented on the most recent scan.
- Presence of measurable disease
- RAS mutation and MMR status must be determined (or tissue availability for testing if not already determined).
- Age 18 years or older.
- ECOG performance status 0-1.
- Life expectancy of at least three months.
Participants with adequate organ function:
- Absolute neutrophil count (ANC) > 1.5 x 109/L
- Hemoglobin > 9 g/dL
- Platelets (PLT) > 70 x 109/L
- AST/ALT < 5 x ULN
- Albumin within normal limits for institution
- Women who are nursing and discontinue nursing prior to enrollment in the program.
- Ability to take oral medication (i.e., no feeding tube).
- Participant able and willing to comply with study procedures as per protocol.
- Participant able to understand and willing to sign and date the written voluntary informed consent form (ICF) at screening visit prior to any protocol-specific procedures.
Exclusion Criteria:
- Participants who have previously received TAS-102.
- Grade 3 or higher peripheral neuropathy (functional impairment).
- Inability to tolerate irinotecan previously (due to uncontrolled diarrhea)
- There are no specific exclusions for bevacizumab. Bevacizumab should be given unless there are specific contraindications per the treating investigator, which should be stated. If UPC is >1.0 (as above) hold bevacizumab until proteinuria resolves and then start bevacizumab.
- Symptomatic CNS metastases requiring treatment.
- Other active malignancy within the last three years (except for non-melanoma skin cancer or a non-invasive/in situ cancer).
- Pregnancy or breast feeding.
- Current therapy with other investigational agents.
- Active infection with body temperature > 38°C due to infection.
- Major surgery within prior four weeks (the surgical incision should be fully healed prior to drug administration).
- Any anticancer therapy within prior two weeks of first dose of study drug.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to TAS-102.
- Current therapy with other investigational agents or participation in another clinical study or any investigational agent received within prior four weeks.
- Grade 3 or higher hypersensitivity reaction to oxaliplatin or irinotecan, or grade 1-2 hypersensitivity reaction to oxaliplatin not controlled with pre-medication.
- Has unresolved toxicity of greater than or equal to Common Terminology Criteria for Adverse (CTCAE) Grade 2 attributed to any prior therapies (excluding anemia, alopecia, skin pigmentation, and platinum-induced neurotoxicity).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tolerability of TAS-102, oxaliplatin, irinotecan with bevacizumab
Each treatment cycle will be fourteen days long.
TAS-102 25 mg/m2 will be taken orally twice daily on days 1-5 of each cycle.
Oxaliplatin 85 mg/m2 infusion will be given on day one for one cycle alternating with Irinotecan 150 mg/m2 infusion, which will be given on day one the next cycle.
|
Participants will be treated with the study drugs until radiological evidence of disease progression or until treatment discontinuation secondary to adverse events.
TAS-OX alternating with TAS-IRI (sequential TASOXIRI) with Bevacizumab, in the treatment of mCRC.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease control rate (DCR):
Time Frame: From baseline until the date of first documented progression of disease, as assessed up to 100 months
|
Defined as the percentage of patients who have achieved complete response (CR), partial response (PR) and stable disease (SD).
The disease control rate will be calculated along with 95% confidence interval.
As Simon's two stage design is used in the study, 95% CI will be calculated for the two-stage nature of the study design.
Response will be determined by independent radiologists using the RECIST criteria.
|
From baseline until the date of first documented progression of disease, as assessed up to 100 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival (PFS)
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, on average up to 100 months
|
Progression Free Survival (PFS) Progression will be assessed by a CT scan according to RECIST criteria version 1.1.
This criterion will be estimated by the median time based on a Kaplan-Meier method.
Patients who have not progressed or died at the time of analysis will be censored at the time of their latest follow-up with clinically stable disease.
This includes participants who withdraw consent.
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, on average up to 100 months
|
Overall Survival (OS)
Time Frame: From date of randomization until the date of death up to 100 months
|
This will be analyzed and plotted using the Kaplan-Meier method.
|
From date of randomization until the date of death up to 100 months
|
Overall Response Rate (ORR)
Time Frame: From the date of randomization and measured through the course of study treatment, assessed up to 100 months
|
This will be calculated along with 95% confidence interval. Response rate is defined as the percentage of subjects with a confirmed complete response (CR) or partial response (PR) by investigator assessment as per RECIST criteria, version 1.1. A maximum of five measurable lesions in total (and up to 2 per organ) representative of all involved organs should be identified as target lesions at baseline and measured through the course of study treatment. At baseline, the sum of the diameters (longest diameters (LD) for extra nodal target lesions and short axis diameters (SAD) for nodal lesions) will be calculated and reported as the baseline sum LD. This baseline sum LD will be used as the reference by which to characterize the objective tumor response. All other lesions should be identified as non-target lesions and should also be recorded at baseline. Measurements of these lesions are not required, but the presence or absence of each should be noted throughout the study |
From the date of randomization and measured through the course of study treatment, assessed up to 100 months
|
Duration of Response
Time Frame: From the date of response until the date of first documented disease progression or death, assessed up to 100 months
|
Response will be determined by independent radiologist using RECIST 1.1.
Time to progression for responders will be analyzed by Kaplan-Meier methods.
|
From the date of response until the date of first documented disease progression or death, assessed up to 100 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Howard S. Hochster, MD, Cancer Institute of New Jersey Rutgers
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase Inhibitors
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Topoisomerase I Inhibitors
- Oxaliplatin
- Bevacizumab
- Irinotecan
Other Study ID Numbers
- 072303
- Pro2023000358 (Other Identifier: Rutgers, The State University of New Jersey)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rectal Cancer
-
Ohio State University Comprehensive Cancer CenterNovartis Pharmaceuticals; National Comprehensive Cancer NetworkCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Recurrent Rectal CancerUnited States
-
M.D. Anderson Cancer CenterRecruitingEvaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Stage IVA Rectal Cancer AJCC v8 | Stage IVB Rectal Cancer AJCC v8 | Stage IVC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage... and other conditionsUnited States
-
OHSU Knight Cancer InstituteNatera, Inc.RecruitingEstablishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Rectal AdenocarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; Taiho Pharmaceutical Co., Ltd.RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8United States
-
Jonsson Comprehensive Cancer CenterNatera, Inc.; The Joseph Drown FoundationRecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8 | Locally...United States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Rectal Adenocarcinoma | Rectal Adenocarcinoma | Stage III Rectal Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Rectal Cancer AJCC v7 | Stage IIIC Rectal Cancer AJCC v7 | Stage IV Rectal Cancer AJCC v7 | Stage IVA Rectal Cancer AJCC v7 | Stage IVB Rectal Cancer AJCC v7 | Locally...United States
-
City of Hope Medical CenterWithdrawnRecurrent Rectal Cancer | Stage I Rectal Cancer | Stage II Rectal Cancer | Stage III Rectal Cancer
Clinical Trials on TAS-102, oxaliplatin, irinotecan with bevacizumab
-
The First Affiliated Hospital of Zhengzhou UniversityNot yet recruiting
-
Cancer Institute and Hospital, Chinese Academy...RecruitingMetastatic Colorectal CancerChina
-
Fudan UniversityRecruitingMetastatic Colorectal Cancer | Colorectal Cancer | Refractory Colorectal CarcinomaChina
-
Taiho Oncology, Inc.CompletedAdvanced Solid TumorsUnited States
-
Providence Health & ServicesTaiho OncologyCompletedRectal CancerUnited States
-
Mayo ClinicNational Comprehensive Cancer NetworkCompletedStage III Gallbladder Cancer AJCC v8 | Stage IIIA Gallbladder Cancer AJCC v8 | Stage IIIB Gallbladder Cancer AJCC v8 | Refractory Gallbladder Carcinoma | Stage IV Gallbladder Cancer AJCC v8 | Stage IV Distal Bile Duct Cancer AJCC v8 | Stage IV Intrahepatic Bile Duct Cancer AJCC v8 | Stage IVB Gallbladder... and other conditionsUnited States
-
PharmaEngineCompletedRefractory Solid TumorsTaiwan
-
The Second Affiliated Hospital of Shandong First...Not yet recruiting
-
Taiho Pharmaceutical Co., Ltd.RecruitingGastric Cancer | Colorectal Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma | Alveolar Soft Part Sarcoma | Advanced or Metastatic Solid TumorJapan
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)Active, not recruitingRecurrent Colon Carcinoma | Metastatic Colorectal Carcinoma | Stage IV Colon Cancer AJCC v7 | Stage IVA Colon Cancer AJCC v7 | Stage IVB Colon Cancer AJCC v7 | Refractory Colorectal CarcinomaUnited States